BDBM50507492 Loxo-195::Selitrectinib::US10966985, Compound 33-B

SMILES C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(C(=O)N1)c3n2

InChI Key InChIKey=OEBIHOVSAMBXIB-SJKOYZFVSA-N

Data  44 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 50507492   

TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  2.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  3.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  2.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  20.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  3.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50:  20.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In DepthDetails US Patent